Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2025-01-29 Director's Dealing
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-01-29 English
Director's Dealing 2025
Director's Dealing
2025-01-29 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-21 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by OnKure Therapeutics, Inc. It includes a prospectus supplement related to a resale of shares, updates on clinical trial data, and references to a press release and investor presentation attached as exhibits. The content focuses on announcements of clinical trial results, safety data, and pipeline progress, rather than detailed financial statements or comprehensive financial performance. The document is not an annual or quarterly report, audit report, earnings release, or management discussion. It is primarily an update on financing (PIPE financing shares resale) and clinical progress, which fits best under Capital/Financing Update (CAP) due to the focus on securities resale and financing-related prospectus supplement. The presence of clinical data announcements does not change the primary nature of the filing as a financing-related update. Therefore, the appropriate classification is CAP with high confidence.
2024-12-10 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by OnKure Therapeutics, Inc. dated December 10, 2024. It announces preliminary clinical trial data and a press release along with an investor presentation posted on the company's website. The content includes clinical trial safety, pharmacokinetic data, and pipeline progress updates. The document is not a full financial report, audit, or earnings release but rather a current report disclosing material events and updates. Form 8-K filings are regulatory filings used to report significant events and are classified under Regulatory Filings (RNS). The document length is over 11,000 characters and contains detailed event disclosure, consistent with an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-12-10 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by OnKure Therapeutics, Inc. It registers shares of common stock under various equity incentive plans. The text includes detailed information about the plans, incorporation by reference of prior SEC filings (10-K, 10-Q, 8-K), indemnification provisions, and exhibits. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital markets filing related to share issuance under employee plans. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual filing, not just an announcement or reference to another report.
2024-12-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.